Provid
Precision
Provid is pursuing MHC inhibition, a novel, fundamental concept to discover drugs for multiple sclerosis (MS) and other autoimmune diseases
Provid
Precision
Provid is pursuing MHC inhibition, a novel, fundamental concept to discover drugs for multiple sclerosis (MS) and other autoimmune diseases
Provid
Precision
Provid is pursuing MHC inhibition, a novel, fundamental concept to discover drugs for multiple sclerosis (MS) and other autoimmune diseases
HLA-DRB1*15:01 (DR15) and MS
PV-3212 Drug Candidate for MS
PV-3212 is a novel, small molecule drug candidate for the treatment of multiple sclerosis (MS). It is a potent and specific inhibitor of the major histocompatibility class II molecule HLA DRB1*1501 (DR15), the immune target genetically associated with MS. Specific inhibition of DR15 promises high efficacy in treating MS in the population carrying this gene without compromising normal immune responses. PV-3212 is a novel, second-generation drug having potent activity, high metabolic stability, and 20+ years of patent life.
The First genetically targeted drug for MS
We target MHC class II molecules that are genetically associated with specific autoimmune diseases and play critical roles in disease pathology.
LEARN MORE
Multiple sclerosis (MS) is strongly associated with the MHC class II molecule HLA-DRB1*15:01 (“DR15“) that binds myelin antigens, engaging autoreactive T cells that initiate attack on the myelin nerve insulation.
LEARN MORE
Provid is developing PV-3212, a potent and highly specific small molecule antagonist of DR15 binding, to disrupt the disease process in MS and other DR15-associated diseases.
LEARN MORE
No current drugs for MS or other autoimmune diseases work via this unique mechanism.
LEARN MORE
PV-3212 blocks DR15 with high potency and is effective in MS disease models but does not compromise other normal immune responses.
LEARN MORE
